Jasper Therapeutics Sees Strategic Shift as Key Shareholder Patrick J. Crutcher Buys Options and Preferred Stock Ahead of Merger‑Driven Capital Raise
Jasper Therapeutics’ insider buys signal a strategic shift: Patrick Crutcher’s new options and preferred stock align with a $132 M merger, hinting at future growth and potential dilution for investors.
3 minutes to read